PCG
MRTX

Private Capital Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Private Capital Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$2K Buy
+31
New +$1.97K ﹤0.01% 1611

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Private Capital Group's MRTX Position: Q2 2022 in Review

Private Capital Group opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022: 31 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1611 among its holdings.

230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Private Capital Group held 31 shares of Mirati Therapeutics, Inc. Common Stock worth $2K as of Q2 2022.
  • Mirati Therapeutics, Inc. Common Stock was a new Private Capital Group position in Q2 2022.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1611 holding.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.